Henlius and Essex Bio Submit Bevacizumab Eye Injection for Approval

China partners Henlius and Essex Bio have filed for approval in their homeland for HLX04-O, a bevacizumab ophthalmic injection for wet age-related macular degeneration (wAMD), based on positive Phase III trial results showing non-inferiority to ranibizumab in visual acuity improvement at 48 weeks. The reformulated version of the biosimilar demonstrated comparable safety profiles in the 388-patient study, with similar ocular and systemic adverse event rates between treatment arms.

HLX04-O blocks VEGF-driven neovascularisation through weekly intravitreal injections. A parallel global Phase III trial is ongoing across China, Australia, the US and EU. wAMD accounts for 90% of AMD-related blindness globally, affecting 30 million patients. The submission positions HLX04-O as a potential cost-effective alternative to existing anti-VEGF therapies in China's rapidly growing ophthalmic market, where ageing populations are driving increased demand for retinal treatments.

PharmCube's NextBiopharm® database lists eight bevacizumab products approved for wAMD, with two more contenders in the global pipeline. Click here to request a free trial for NextBiopharm®.

Daily News
Regeneron, Telix Shake on Next-Gen Radiopharmaceuticals
2026-04-14
Revolution Med's Pan-RAS Inhibitor Succeeds in Pivotal Phase III Trial
2026-04-14
Gilead Exercises Option to License Kymera's First-in-Class CDK2 Degrader
2026-04-13
Haisco Licenses 2 Nav1.8 Inhibitors to AbbVie in Deal Worth up to USD 745m
2026-04-13
BMS Launches First Innovation Centre in China to Drive Collaboration
2026-04-10
Latest Report
Global Drug Progress Report during January 2026
Details